Send this to a friend

Ocata Therapeutics purchased for $384M

Tokyo’s Astellas Pharma Inc. has completed its $384 million purchase of Marlborough’s Ocata Therapeutics.
Astellas completed the purchase of all outstanding stock for Ocata Therapeutics, which researches treatments for eye diseases, through its subsidiary Laurel Acquisition Inc. Laurel was then merged into Ocata ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media